nanoTherics Launches magnefect-nano II™
Complete the form below to unlock access to ALL audio articles.
nanoTherics has announced launch of the magnefect-nano II™. This new, compact device offers gene transfection with improved efficiencies and cell viabilities, even with a range of difficult cell types such as neuronal and primary cells.
It uses a unique technology applying proprietary magnet configurations and oscillating magnet arrays, which can operate at user-definable variable frequencies, to promote magnetic nanoparticle/DNA uptake into cells to improve non-viral gene transfection, whilst maintaining high cell viability.
It is simple to use with low running costs (as low as $0.1 per transfection). The device provides improved transfection efficiency and effectiveness over the best currently available cationic lipid agents at short transfection times (<30 minutes). It allows retransfection as well as adherent state transfection for user flexibility.
It has been launched as a more compact system to replace the magnefect-nano, which the Company introduced in 2009, and offers full flexibility with interchangeable 6-well, 24-well and 96-well array formats and variable oscillating frequency capability to enable researchers to optimize protocols specifically for the cell types they are using.
Dr Linda E Cammish, Chief Executive Officer, said, “We are delighted to be adding the magnefect-nano II to our product portfolio to enable our customers to improve transfection efficiencies in their research even with hard to transfect cells such as neuronal and primary cells”.
She added, “The system has been designed as a direct result of customer feedback to provide a more compact system reducing the valuable laboratory bench and incubator space needs by users. It continues to offer the benefits that oscillating magnet assisted transfection provides such as the high transfection efficiencies and cell viabilities, short transfection times and low running costs.”
